HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Apr.22) - TCM VBP Results, R&D Thinking Mode, Biotech Delisting

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play

WuXi AppTec Co Ltd (2359.HK/603259.CH) 2022Q1 - Some Points Worth the Attention

The Impact of America COMPETES Act on China Healthcare – Supply Chain Decoupling?

Sino Biopharmaceutical (1177.HK) - Three “Golden Eggs” and the Risks Behind

The Concerns and Outlook About the Recent Rally in Traditional Chinese Medicine (TCM) Sector

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. (600436 CH)

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

<ul>
<li>The recent outbreak and lockdown measures in Shanghai are radically changing China's healthcare market landscape. The complexity of the Chinese market will be further exacerbated by COVID-19.</li>
<li>We analyzed the impact on medical insurance fund, hospital operations, pharmaceutical and medical device companies, digital healthcare platforms, drug R&amp;D progress, supply chain, IVD companies, and traditional Chinese medicine(TCM) sector.</li>
<li>The pandemic in Shanghai will have a far-reaching impact on China's future development.This is not just a battle over COVID-19,but the future of RMB and the fortune/destiny of a nation</li>
</ul>


The recent outbreak and lockdown measures in Shanghai are radically changing China's healthcare market landscape. The complexity of the Chinese market will be further exacerbated by COVID-19.
We analyzed the impact on medical insurance fund, hospital operations, pharmaceutical and medical device companies, digital healthcare platforms, drug R&amp;D progress, supply chain, IVD companies, and traditional Chinese medicine(TCM) sector.
The pandemic in Shanghai will have a far-reaching impact on China's future development.This is not just a battle over COVID-19,but the future of RMB and the fortune/destiny of a nation


The Impact of COVID-19 and Shanghai Lockdown on China Healthcare